Latest Pharma Insights
Bial Ends Development Of Parkinson’s Disease Drug After Phase IIb Fail
The Portuguese drugmaker said BIA 28-6156 did not achieve the primary and key secondary endpoints in a Phase IIb trial of the drug in Parkinson’s patients with a GBA1 gene variant.
Scrip - June 9, 2026
The Portuguese drugmaker said BIA 28-6156 did not achieve the primary and key secondary endpoints in a Phase IIb trial of the drug in Parkinson’s patients with a GBA1 gene variant.
Scrip - June 9, 2026
UBS: Lilly Still Set To Lead Obesity Market, Despite Novo Gains With Wegovy Pill
UBS analyst Michael Yee says Lilly’s Zepbound, Foundayo and retatrutide are well positioned to stay on top in the obesity market despite Novo Nordisk’s early Wegovy pill momentum.
Scrip - June 9, 2026
UBS analyst Michael Yee says Lilly’s Zepbound, Foundayo and retatrutide are well positioned to stay on top in the obesity market despite Novo Nordisk’s early Wegovy pill momentum.
Scrip - June 9, 2026
ASCO: Novartis To Face Challenges In Growing Radiopharmaceutical Space
The Swiss drugmaker presented data at ASCO for Pluvicto as well as its next-generation asset 225Ac-PSMA-617 in prostate cancer. Telix and Convergent also showcased their next-generation candidates.
Scrip - June 9, 2026
The Swiss drugmaker presented data at ASCO for Pluvicto as well as its next-generation asset 225Ac-PSMA-617 in prostate cancer. Telix and Convergent also showcased their next-generation candidates.
Scrip - June 9, 2026
Early-Stage Biotechs Miss Out As VC Investors Focus On Mega-Rounds
Venture capital funding is readily available to biotechs with later-stage programs, but for earlier-stage firms, a financing squeeze is on and narrowing focus is a possible solution, EY report authors said.
Scrip - June 9, 2026
Venture capital funding is readily available to biotechs with later-stage programs, but for earlier-stage firms, a financing squeeze is on and narrowing focus is a possible solution, EY report authors said.
Scrip - June 9, 2026
City Therapeutics Raises $99.5m To Take More RNAi Drugs Into The Clinic
City’s siRNA drug targeting Factor XI is in Phase I and the company plans to take two more programs into the clinic soon while seeking partners for its CITY RNA platform.
Scrip - June 9, 2026
City’s siRNA drug targeting Factor XI is in Phase I and the company plans to take two more programs into the clinic soon while seeking partners for its CITY RNA platform.
Scrip - June 9, 2026
FDA Early Alert Flags Expiratory-Valve Defect In Hamilton Coaxial Breathing Circuit Sets
The FDA has issued an early alert for coaxial breathing circuit sets used with three Hamilton ventilator models, prompting a field correction to the devices' instructions for use. The company is reporting four serious injuries linked to the issue.
Medtech Insight - June 9, 2026
The FDA has issued an early alert for coaxial breathing circuit sets used with three Hamilton ventilator models, prompting a field correction to the devices' instructions for use. The company is reporting four serious injuries linked to the issue.
Medtech Insight - June 9, 2026
From Medtronic to Smith & Nephew: Medtech’s Biggest Names Accelerate M&A Across Earnings Season
Medtech's latest earnings season was a deal briefing. Balance sheets are ready, valuations are moving, and the industry's biggest names are closing transactions — not just signaling intent.
Medtech Insight - June 9, 2026
Medtech's latest earnings season was a deal briefing. Balance sheets are ready, valuations are moving, and the industry's biggest names are closing transactions — not just signaling intent.
Medtech Insight - June 9, 2026
GSK Is Scaling Up Its Cancer Ambitions With Nuvalent Buyout
The acquisition brings two potential best-in-class assets which GSK will add to its existing presence in targeted lung cancer therapy.
Scrip - June 9, 2026
The acquisition brings two potential best-in-class assets which GSK will add to its existing presence in targeted lung cancer therapy.
Scrip - June 9, 2026
Topical Prednisolone On The Agenda For German Switch Committee
Germany's SVA will discuss a potential Rx-to-OTC switch for topical prednisolone at its next meeting on 21 July, along with applications relating to hyoscyami folium et herba, digitoxin and olopatadine.
HBW Insight - June 9, 2026
Germany's SVA will discuss a potential Rx-to-OTC switch for topical prednisolone at its next meeting on 21 July, along with applications relating to hyoscyami folium et herba, digitoxin and olopatadine.
HBW Insight - June 9, 2026
ADA 2026: Lilly Showcases ACHIEVE Data To Support Foundayo’s Move Into Diabetes
The diabetes data arrive just weeks after Foundayo's US launch in obesity, with Lilly now seeking to extend the oral GLP-1's reach into a second major indication.
Scrip - June 9, 2026
The diabetes data arrive just weeks after Foundayo's US launch in obesity, with Lilly now seeking to extend the oral GLP-1's reach into a second major indication.
Scrip - June 9, 2026
Indian Court Overturns Injunction Against Intas’s Bevatas, Faults Sun
A Division Bench of the Delhi High Court has set aside a single Judge's order permanently restraining Intas from using the mark 'Bevatas' for its bevacizumab biosimilar and has rebuked complainant Sun Pharma for its conduct.
Generics Bulletin - June 9, 2026
A Division Bench of the Delhi High Court has set aside a single Judge's order permanently restraining Intas from using the mark 'Bevatas' for its bevacizumab biosimilar and has rebuked complainant Sun Pharma for its conduct.
Generics Bulletin - June 9, 2026
Apotex Leads The Way On Januvia And Janumet Generics
Apotex is amongst the first to commercially launch its Januvia and Janumet generics, as it begins a shared 180-day shared exclusivity period launching both its sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, indicated for the treatment of type 2 diabetes mellitus.
Generics Bulletin - June 9, 2026
Apotex is amongst the first to commercially launch its Januvia and Janumet generics, as it begins a shared 180-day shared exclusivity period launching both its sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, indicated for the treatment of type 2 diabetes mellitus.
Generics Bulletin - June 9, 2026
Mixed Verdict For Gilead-Merck Alliance With HIV Win, Trodelvy NSCLC Failure
Gilead and Merck's HIV alliance cleared a Phase III bar the same day a cancer trial collaboration collapsed – a split verdict on two franchises central to both companies' futures.
Scrip - June 9, 2026
Gilead and Merck's HIV alliance cleared a Phase III bar the same day a cancer trial collaboration collapsed – a split verdict on two franchises central to both companies' futures.
Scrip - June 9, 2026
The Medtech Investment Gap: How Europe Loses Capital It Could Capture
Europe holds 27% of the global medtech market and some of its most active innovation clusters, but captures barely a fifth of global venture capital. That gap is not a funding problem. It is a failure to convert scientific strength into scalable businesses.
In Vivo - June 9, 2026
Europe holds 27% of the global medtech market and some of its most active innovation clusters, but captures barely a fifth of global venture capital. That gap is not a funding problem. It is a failure to convert scientific strength into scalable businesses.
In Vivo - June 9, 2026
EULAR: Argenx CMO Muses On Vyvgart, Myositis And More
Luc Truyen tells Scrip about indication expansions for the firm’s mega-blockbuster and broadening the pipeline beyond FcRn inhibition.
Scrip - June 9, 2026
Luc Truyen tells Scrip about indication expansions for the firm’s mega-blockbuster and broadening the pipeline beyond FcRn inhibition.
Scrip - June 9, 2026
Senseonics At ADA 2026: Direct Sales Control, Real-World Data, And Roadmap To An Invisible CGM
Senseonics used ADA 2026 to argue its once-a-year implantable CGM is a structural alternative to Abbott and Dexcom — backed by 70–82% projected revenue growth, a new in-house sales team, and a pipeline ending with a fully invisible sensor.
Medtech Insight - June 9, 2026
Senseonics used ADA 2026 to argue its once-a-year implantable CGM is a structural alternative to Abbott and Dexcom — backed by 70–82% projected revenue growth, a new in-house sales team, and a pipeline ending with a fully invisible sensor.
Medtech Insight - June 9, 2026
BsUFA IV: If Dates Known, US FDA Looks To Speed Biosimilar Approval Once Exclusivity Expires
The FDA proposed a goal date for biosimilars that are approvable and waiting for exclusivity to run out, but industry said expiration dates often are unknown.
Generics Bulletin - June 9, 2026
The FDA proposed a goal date for biosimilars that are approvable and waiting for exclusivity to run out, but industry said expiration dates often are unknown.
Generics Bulletin - June 9, 2026
OTC Availability Of Codeine Under Review By UK MHRA
Exclusive: MHRA is considering further risk minimization measures for codeine including whether products containing the opioid should continue to be available without a prescription in the UK.
HBW Insight - June 9, 2026
Exclusive: MHRA is considering further risk minimization measures for codeine including whether products containing the opioid should continue to be available without a prescription in the UK.
HBW Insight - June 9, 2026
Stock Watch: Gene Therapy Commercialization Faces A Reckoning
Despite multi-million-dollar price tags, the commercialization of innovative gene therapies for small patient populations largely remains a struggle in 2026. As new products target even rarer indications, an alternative approach appears.
Scrip - June 9, 2026
Despite multi-million-dollar price tags, the commercialization of innovative gene therapies for small patient populations largely remains a struggle in 2026. As new products target even rarer indications, an alternative approach appears.
Scrip - June 9, 2026
Reactions Roll In As Curtain Closes On The Hikma-Amarin Supreme Court Case
Hikma has secured victory in the long-running litigation with Amarin over skinny-label generic carve-outs. While the SCOTUS decision preserved the skinny-label regime, the grounds will be tested by future litigations.
Generics Bulletin - June 9, 2026
Hikma has secured victory in the long-running litigation with Amarin over skinny-label generic carve-outs. While the SCOTUS decision preserved the skinny-label regime, the grounds will be tested by future litigations.
Generics Bulletin - June 9, 2026
Alvotech Takes The Lead On Vedolizumab
Alvotech has secured FDA review of its proposed interchangeable intravenous Entyvio biosimilar AVT16, adding to EMA validation of a broader vedolizumab filing covering both IV and subcutaneous versions.
Generics Bulletin - June 9, 2026
Alvotech has secured FDA review of its proposed interchangeable intravenous Entyvio biosimilar AVT16, adding to EMA validation of a broader vedolizumab filing covering both IV and subcutaneous versions.
Generics Bulletin - June 9, 2026
ADA 2026: Novo Aiming For Second Or Third Time Lucky In Amylins
Hoping to gain a first approval for CagriSema later this year, Novo wants to squeeze out more efficacy from its amylins with further studies of the combination and of its next-generation asset.
Scrip - June 9, 2026
Hoping to gain a first approval for CagriSema later this year, Novo wants to squeeze out more efficacy from its amylins with further studies of the combination and of its next-generation asset.
Scrip - June 9, 2026
GSK Moves Back Into Big M&A With Nuvalent Buy
The UK major closes on a cancer deal that represents its second biggest ever and brings with it two cancer assets that could launch this year.
Scrip - June 9, 2026
The UK major closes on a cancer deal that represents its second biggest ever and brings with it two cancer assets that could launch this year.
Scrip - June 9, 2026
AI Is Going From ‘Abstract To Practical’ For Clinicians, Says Philips’ Future Health Index
AI is moving from the periphery to front and center for healthcare providers – but unevenly, says Royal Philips in its 2026 Future Health Index survey, published today.
Medtech Insight - June 9, 2026
AI is moving from the periphery to front and center for healthcare providers – but unevenly, says Royal Philips in its 2026 Future Health Index survey, published today.
Medtech Insight - June 9, 2026
Trusting Startups Without Taking A Stake: What AstraZeneca’s BioVentureHub Has Learned
AstraZeneca's BioVentureHub CEO Magnus Björsne explains why a trust-based, no-equity model outperforms conventional pharma partnering – and how the Gothenburg hub is now targeting sustainability as its next frontier.
In Vivo - June 9, 2026
AstraZeneca's BioVentureHub CEO Magnus Björsne explains why a trust-based, no-equity model outperforms conventional pharma partnering – and how the Gothenburg hub is now targeting sustainability as its next frontier.
In Vivo - June 9, 2026
ADA 2026: Raynovent’s Biweekly GIP/GLP-1 Injectable Shows Broad Range Of Weight Loss
Raynovent Biotech’s first-in-class biweekly GIP/GLP-1 receptor agonist RAY1225 shows up to 21.18% weight reduction at 24 weeks in data from a China Phase II trial presented at the American Diabetes Association meeting.
Scrip - June 9, 2026
Raynovent Biotech’s first-in-class biweekly GIP/GLP-1 receptor agonist RAY1225 shows up to 21.18% weight reduction at 24 weeks in data from a China Phase II trial presented at the American Diabetes Association meeting.
Scrip - June 9, 2026
From Genome To RUO In Six Days: Roche’s Playbook For Rapid Outbreak Diagnostics
CEO Marcus Droege on how the Roche subsidiary, TIB MOLBIOL, leveraged its infrastructure to design and validate a Bundibugyo Ebola PCR assay in six days.
Medtech Insight - June 9, 2026
CEO Marcus Droege on how the Roche subsidiary, TIB MOLBIOL, leveraged its infrastructure to design and validate a Bundibugyo Ebola PCR assay in six days.
Medtech Insight - June 9, 2026
12-Month VISIONARY Data Support Otsuka’s Sibeprenlimab On Road To Standard Approval
Interim results for first-in-class drug show long-term preservation of kidney function, seen as key in controlling IgA nephropathy progression.
Scrip - June 9, 2026
Interim results for first-in-class drug show long-term preservation of kidney function, seen as key in controlling IgA nephropathy progression.
Scrip - June 9, 2026
Everest On Licensing Spree After Investors Raise Stakes
Following recent investor signals of confidence, Everest signs flurry of new deals to build its innovative portfolio in APAC.
Scrip - June 9, 2026
Following recent investor signals of confidence, Everest signs flurry of new deals to build its innovative portfolio in APAC.
Scrip - June 9, 2026
Bial Ends Development Of Parkinson’s Disease Drug After Phase IIb Fail
The Portuguese drugmaker said BIA 28-6156 did not achieve the primary and key secondary endpoints in a Phase IIb trial of the drug in Parkinson’s patients with a GBA1 gene variant.
Scrip - June 9, 2026
The Portuguese drugmaker said BIA 28-6156 did not achieve the primary and key secondary endpoints in a Phase IIb trial of the drug in Parkinson’s patients with a GBA1 gene variant.
Scrip - June 9, 2026
UBS: Lilly Still Set To Lead Obesity Market, Despite Novo Gains With Wegovy Pill
UBS analyst Michael Yee says Lilly’s Zepbound, Foundayo and retatrutide are well positioned to stay on top in the obesity market despite Novo Nordisk’s early Wegovy pill momentum.
Scrip - June 9, 2026
UBS analyst Michael Yee says Lilly’s Zepbound, Foundayo and retatrutide are well positioned to stay on top in the obesity market despite Novo Nordisk’s early Wegovy pill momentum.
Scrip - June 9, 2026
ASCO: Novartis To Face Challenges In Growing Radiopharmaceutical Space
The Swiss drugmaker presented data at ASCO for Pluvicto as well as its next-generation asset 225Ac-PSMA-617 in prostate cancer. Telix and Convergent also showcased their next-generation candidates.
Scrip - June 9, 2026
The Swiss drugmaker presented data at ASCO for Pluvicto as well as its next-generation asset 225Ac-PSMA-617 in prostate cancer. Telix and Convergent also showcased their next-generation candidates.
Scrip - June 9, 2026
Early-Stage Biotechs Miss Out As VC Investors Focus On Mega-Rounds
Venture capital funding is readily available to biotechs with later-stage programs, but for earlier-stage firms, a financing squeeze is on and narrowing focus is a possible solution, EY report authors said.
Scrip - June 9, 2026
Venture capital funding is readily available to biotechs with later-stage programs, but for earlier-stage firms, a financing squeeze is on and narrowing focus is a possible solution, EY report authors said.
Scrip - June 9, 2026
City Therapeutics Raises $99.5m To Take More RNAi Drugs Into The Clinic
City’s siRNA drug targeting Factor XI is in Phase I and the company plans to take two more programs into the clinic soon while seeking partners for its CITY RNA platform.
Scrip - June 9, 2026
City’s siRNA drug targeting Factor XI is in Phase I and the company plans to take two more programs into the clinic soon while seeking partners for its CITY RNA platform.
Scrip - June 9, 2026
GSK Is Scaling Up Its Cancer Ambitions With Nuvalent Buyout
The acquisition brings two potential best-in-class assets which GSK will add to its existing presence in targeted lung cancer therapy.
Scrip - June 9, 2026
The acquisition brings two potential best-in-class assets which GSK will add to its existing presence in targeted lung cancer therapy.
Scrip - June 9, 2026
ADA 2026: Lilly Showcases ACHIEVE Data To Support Foundayo’s Move Into Diabetes
The diabetes data arrive just weeks after Foundayo's US launch in obesity, with Lilly now seeking to extend the oral GLP-1's reach into a second major indication.
Scrip - June 9, 2026
The diabetes data arrive just weeks after Foundayo's US launch in obesity, with Lilly now seeking to extend the oral GLP-1's reach into a second major indication.
Scrip - June 9, 2026
Mixed Verdict For Gilead-Merck Alliance With HIV Win, Trodelvy NSCLC Failure
Gilead and Merck's HIV alliance cleared a Phase III bar the same day a cancer trial collaboration collapsed – a split verdict on two franchises central to both companies' futures.
Scrip - June 9, 2026
Gilead and Merck's HIV alliance cleared a Phase III bar the same day a cancer trial collaboration collapsed – a split verdict on two franchises central to both companies' futures.
Scrip - June 9, 2026
EULAR: Argenx CMO Muses On Vyvgart, Myositis And More
Luc Truyen tells Scrip about indication expansions for the firm’s mega-blockbuster and broadening the pipeline beyond FcRn inhibition.
Scrip - June 9, 2026
Luc Truyen tells Scrip about indication expansions for the firm’s mega-blockbuster and broadening the pipeline beyond FcRn inhibition.
Scrip - June 9, 2026
Stock Watch: Gene Therapy Commercialization Faces A Reckoning
Despite multi-million-dollar price tags, the commercialization of innovative gene therapies for small patient populations largely remains a struggle in 2026. As new products target even rarer indications, an alternative approach appears.
Scrip - June 9, 2026
Despite multi-million-dollar price tags, the commercialization of innovative gene therapies for small patient populations largely remains a struggle in 2026. As new products target even rarer indications, an alternative approach appears.
Scrip - June 9, 2026
ADA 2026: Novo Aiming For Second Or Third Time Lucky In Amylins
Hoping to gain a first approval for CagriSema later this year, Novo wants to squeeze out more efficacy from its amylins with further studies of the combination and of its next-generation asset.
Scrip - June 9, 2026
Hoping to gain a first approval for CagriSema later this year, Novo wants to squeeze out more efficacy from its amylins with further studies of the combination and of its next-generation asset.
Scrip - June 9, 2026
GSK Moves Back Into Big M&A With Nuvalent Buy
The UK major closes on a cancer deal that represents its second biggest ever and brings with it two cancer assets that could launch this year.
Scrip - June 9, 2026
The UK major closes on a cancer deal that represents its second biggest ever and brings with it two cancer assets that could launch this year.
Scrip - June 9, 2026
ADA 2026: Raynovent’s Biweekly GIP/GLP-1 Injectable Shows Broad Range Of Weight Loss
Raynovent Biotech’s first-in-class biweekly GIP/GLP-1 receptor agonist RAY1225 shows up to 21.18% weight reduction at 24 weeks in data from a China Phase II trial presented at the American Diabetes Association meeting.
Scrip - June 9, 2026
Raynovent Biotech’s first-in-class biweekly GIP/GLP-1 receptor agonist RAY1225 shows up to 21.18% weight reduction at 24 weeks in data from a China Phase II trial presented at the American Diabetes Association meeting.
Scrip - June 9, 2026
12-Month VISIONARY Data Support Otsuka’s Sibeprenlimab On Road To Standard Approval
Interim results for first-in-class drug show long-term preservation of kidney function, seen as key in controlling IgA nephropathy progression.
Scrip - June 9, 2026
Interim results for first-in-class drug show long-term preservation of kidney function, seen as key in controlling IgA nephropathy progression.
Scrip - June 9, 2026
Everest On Licensing Spree After Investors Raise Stakes
Following recent investor signals of confidence, Everest signs flurry of new deals to build its innovative portfolio in APAC.
Scrip - June 9, 2026
Following recent investor signals of confidence, Everest signs flurry of new deals to build its innovative portfolio in APAC.
Scrip - June 9, 2026
FDA Early Alert Flags Expiratory-Valve Defect In Hamilton Coaxial Breathing Circuit Sets
The FDA has issued an early alert for coaxial breathing circuit sets used with three Hamilton ventilator models, prompting a field correction to the devices' instructions for use. The company is reporting four serious injuries linked to the issue.
Medtech Insight - June 9, 2026
The FDA has issued an early alert for coaxial breathing circuit sets used with three Hamilton ventilator models, prompting a field correction to the devices' instructions for use. The company is reporting four serious injuries linked to the issue.
Medtech Insight - June 9, 2026
From Medtronic to Smith & Nephew: Medtech’s Biggest Names Accelerate M&A Across Earnings Season
Medtech's latest earnings season was a deal briefing. Balance sheets are ready, valuations are moving, and the industry's biggest names are closing transactions — not just signaling intent.
Medtech Insight - June 9, 2026
Medtech's latest earnings season was a deal briefing. Balance sheets are ready, valuations are moving, and the industry's biggest names are closing transactions — not just signaling intent.
Medtech Insight - June 9, 2026
Senseonics At ADA 2026: Direct Sales Control, Real-World Data, And Roadmap To An Invisible CGM
Senseonics used ADA 2026 to argue its once-a-year implantable CGM is a structural alternative to Abbott and Dexcom — backed by 70–82% projected revenue growth, a new in-house sales team, and a pipeline ending with a fully invisible sensor.
Medtech Insight - June 9, 2026
Senseonics used ADA 2026 to argue its once-a-year implantable CGM is a structural alternative to Abbott and Dexcom — backed by 70–82% projected revenue growth, a new in-house sales team, and a pipeline ending with a fully invisible sensor.
Medtech Insight - June 9, 2026
AI Is Going From ‘Abstract To Practical’ For Clinicians, Says Philips’ Future Health Index
AI is moving from the periphery to front and center for healthcare providers – but unevenly, says Royal Philips in its 2026 Future Health Index survey, published today.
Medtech Insight - June 9, 2026
AI is moving from the periphery to front and center for healthcare providers – but unevenly, says Royal Philips in its 2026 Future Health Index survey, published today.
Medtech Insight - June 9, 2026
From Genome To RUO In Six Days: Roche’s Playbook For Rapid Outbreak Diagnostics
CEO Marcus Droege on how the Roche subsidiary, TIB MOLBIOL, leveraged its infrastructure to design and validate a Bundibugyo Ebola PCR assay in six days.
Medtech Insight - June 9, 2026
CEO Marcus Droege on how the Roche subsidiary, TIB MOLBIOL, leveraged its infrastructure to design and validate a Bundibugyo Ebola PCR assay in six days.
Medtech Insight - June 9, 2026
Topical Prednisolone On The Agenda For German Switch Committee
Germany's SVA will discuss a potential Rx-to-OTC switch for topical prednisolone at its next meeting on 21 July, along with applications relating to hyoscyami folium et herba, digitoxin and olopatadine.
HBW Insight - June 9, 2026
Germany's SVA will discuss a potential Rx-to-OTC switch for topical prednisolone at its next meeting on 21 July, along with applications relating to hyoscyami folium et herba, digitoxin and olopatadine.
HBW Insight - June 9, 2026
OTC Availability Of Codeine Under Review By UK MHRA
Exclusive: MHRA is considering further risk minimization measures for codeine including whether products containing the opioid should continue to be available without a prescription in the UK.
HBW Insight - June 9, 2026
Exclusive: MHRA is considering further risk minimization measures for codeine including whether products containing the opioid should continue to be available without a prescription in the UK.
HBW Insight - June 9, 2026
Indian Court Overturns Injunction Against Intas’s Bevatas, Faults Sun
A Division Bench of the Delhi High Court has set aside a single Judge's order permanently restraining Intas from using the mark 'Bevatas' for its bevacizumab biosimilar and has rebuked complainant Sun Pharma for its conduct.
Generics Bulletin - June 9, 2026
A Division Bench of the Delhi High Court has set aside a single Judge's order permanently restraining Intas from using the mark 'Bevatas' for its bevacizumab biosimilar and has rebuked complainant Sun Pharma for its conduct.
Generics Bulletin - June 9, 2026
Apotex Leads The Way On Januvia And Janumet Generics
Apotex is amongst the first to commercially launch its Januvia and Janumet generics, as it begins a shared 180-day shared exclusivity period launching both its sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, indicated for the treatment of type 2 diabetes mellitus.
Generics Bulletin - June 9, 2026
Apotex is amongst the first to commercially launch its Januvia and Janumet generics, as it begins a shared 180-day shared exclusivity period launching both its sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, indicated for the treatment of type 2 diabetes mellitus.
Generics Bulletin - June 9, 2026
BsUFA IV: If Dates Known, US FDA Looks To Speed Biosimilar Approval Once Exclusivity Expires
The FDA proposed a goal date for biosimilars that are approvable and waiting for exclusivity to run out, but industry said expiration dates often are unknown.
Generics Bulletin - June 9, 2026
The FDA proposed a goal date for biosimilars that are approvable and waiting for exclusivity to run out, but industry said expiration dates often are unknown.
Generics Bulletin - June 9, 2026
Reactions Roll In As Curtain Closes On The Hikma-Amarin Supreme Court Case
Hikma has secured victory in the long-running litigation with Amarin over skinny-label generic carve-outs. While the SCOTUS decision preserved the skinny-label regime, the grounds will be tested by future litigations.
Generics Bulletin - June 9, 2026
Hikma has secured victory in the long-running litigation with Amarin over skinny-label generic carve-outs. While the SCOTUS decision preserved the skinny-label regime, the grounds will be tested by future litigations.
Generics Bulletin - June 9, 2026
Alvotech Takes The Lead On Vedolizumab
Alvotech has secured FDA review of its proposed interchangeable intravenous Entyvio biosimilar AVT16, adding to EMA validation of a broader vedolizumab filing covering both IV and subcutaneous versions.
Generics Bulletin - June 9, 2026
Alvotech has secured FDA review of its proposed interchangeable intravenous Entyvio biosimilar AVT16, adding to EMA validation of a broader vedolizumab filing covering both IV and subcutaneous versions.
Generics Bulletin - June 9, 2026
The Medtech Investment Gap: How Europe Loses Capital It Could Capture
Europe holds 27% of the global medtech market and some of its most active innovation clusters, but captures barely a fifth of global venture capital. That gap is not a funding problem. It is a failure to convert scientific strength into scalable businesses.
In Vivo - June 9, 2026
Europe holds 27% of the global medtech market and some of its most active innovation clusters, but captures barely a fifth of global venture capital. That gap is not a funding problem. It is a failure to convert scientific strength into scalable businesses.
In Vivo - June 9, 2026
Trusting Startups Without Taking A Stake: What AstraZeneca’s BioVentureHub Has Learned
AstraZeneca's BioVentureHub CEO Magnus Björsne explains why a trust-based, no-equity model outperforms conventional pharma partnering – and how the Gothenburg hub is now targeting sustainability as its next frontier.
In Vivo - June 9, 2026
AstraZeneca's BioVentureHub CEO Magnus Björsne explains why a trust-based, no-equity model outperforms conventional pharma partnering – and how the Gothenburg hub is now targeting sustainability as its next frontier.
In Vivo - June 9, 2026